ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $372,767 | -47.6% | 17,419 | -1.1% | 0.00% | -57.1% |
| Q1 2023 | $712,027 | +116817.4% | 17,607 | +34.4% | 0.01% | -22.2% |
| Q4 2022 | $609 | -99.9% | 13,097 | -6.6% | 0.01% | -25.0% |
| Q3 2022 | $727,000 | +15.4% | 14,016 | +5.2% | 0.01% | +20.0% |
| Q2 2022 | $630,000 | -31.6% | 13,324 | +3.0% | 0.01% | -23.1% |
| Q1 2022 | $921,000 | -5.1% | 12,939 | -0.2% | 0.01% | +8.3% |
| Q4 2021 | $970,000 | +28.3% | 12,970 | -2.5% | 0.01% | +33.3% |
| Q3 2021 | $756,000 | +28.4% | 13,309 | -0.6% | 0.01% | +28.6% |
| Q2 2021 | $589,000 | -11.0% | 13,394 | -0.1% | 0.01% | -12.5% |
| Q1 2021 | $662,000 | +9.6% | 13,413 | -6.5% | 0.01% | 0.0% |
| Q4 2020 | $604,000 | -20.9% | 14,349 | -14.0% | 0.01% | -20.0% |
| Q3 2020 | $764,000 | +18.8% | 16,687 | +30.3% | 0.01% | 0.0% |
| Q2 2020 | $643,000 | -7.7% | 12,802 | -5.6% | 0.01% | -23.1% |
| Q1 2020 | $697,000 | +3.3% | 13,559 | +24.1% | 0.01% | +30.0% |
| Q4 2019 | $675,000 | +3.5% | 10,929 | +0.7% | 0.01% | 0.0% |
| Q3 2019 | $652,000 | -28.5% | 10,851 | +0.4% | 0.01% | -28.6% |
| Q2 2019 | $912,000 | -10.7% | 10,813 | +1.1% | 0.01% | -12.5% |
| Q1 2019 | $1,021,000 | +40.1% | 10,693 | +3.9% | 0.02% | +23.1% |
| Q4 2018 | $729,000 | -13.6% | 10,296 | +4.3% | 0.01% | +8.3% |
| Q3 2018 | $844,000 | -21.9% | 9,876 | +5.9% | 0.01% | -20.0% |
| Q2 2018 | $1,081,000 | +40.6% | 9,327 | -1.9% | 0.02% | +50.0% |
| Q1 2018 | $769,000 | +35.9% | 9,509 | -1.5% | 0.01% | +42.9% |
| Q4 2017 | $566,000 | +16.0% | 9,651 | -7.4% | 0.01% | +16.7% |
| Q3 2017 | $488,000 | +33.7% | 10,423 | +2.7% | 0.01% | +20.0% |
| Q2 2017 | $365,000 | +17.7% | 10,146 | +0.8% | 0.01% | +25.0% |
| Q1 2017 | $310,000 | -8.8% | 10,061 | -0.7% | 0.00% | -20.0% |
| Q4 2016 | $340,000 | +20.6% | 10,135 | -4.3% | 0.01% | +25.0% |
| Q3 2016 | $282,000 | +25.9% | 10,586 | +4.3% | 0.00% | +33.3% |
| Q2 2016 | $224,000 | -27.7% | 10,147 | -4.0% | 0.00% | -25.0% |
| Q1 2016 | $310,000 | -13.6% | 10,566 | -2.7% | 0.00% | 0.0% |
| Q4 2015 | $359,000 | -8.2% | 10,863 | +0.3% | 0.00% | -20.0% |
| Q3 2015 | $391,000 | – | 10,829 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |